T1	Participants 1280 1364	EMIAT enrolled 1486 patients (743 in the amiodarone group, 743 in the placebo group)
T2	Participants 1398 1540	All-cause mortality (103 deaths in the amiodarone group, 102 in the placebo group) and cardiac mortality did not differ between the two groups
T3	Participants 1115 1213	survivors of myocardial infarction with a left-ventricular ejection fraction (LVEF) of 40% or less
